ATI vs USPH: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
ATI is the larger of the two ($22.58B market cap): the incumbent the market prices for continued execution (24.83x forward earnings, beta 1.07). USPH is the smaller challenger ($1.43B), priced similarly on forward earnings (28.55x): more room to run, but more to prove. If the story you believe is ATI's (Commercial aerospace recovery and ramp), ATI is the more direct way to own it; if it is USPH's (Hospital affiliations), USPH is.
ATI vs USPH: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ATI | USPH | What it tells you |
|---|---|---|---|
| Market cap | $22.58B | $1.43B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 24.83 | 28.55 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.07 | 1.13 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 49% of range | 87% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 11.26 | 3.34 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ATI and USPH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATI and USPH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATI and USPH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does ATI Inc. (ATI) do?
ATI Inc. (ATI), formerly Allegheny Technologies, is a specialty materials and components producer focused on high-performance metals for demanding applications. Its core markets are aerospace and defense, where ATI supplies titanium, nickel-based superalloys, and other advanced alloys used in jet engines, airframes, and defense systems that must withstand extreme heat, stress, and corrosion. The company also serves medical, energy, electronics, and specialty industrial markets. ATI operates through two segments: High Performance Materials and Components (jet engine parts, forgings, and advanced alloys) and Advanced Alloys and Solutions (specialty rolled products and materials). The company has deliberately repositioned over the past several years away from lower-margin commodity stainless toward higher-value, harder-to-make aerospace and defense materials where it has technical differentiation and long qualification cycles that lock in customer relationships. Founded through the combination of specialty metals businesses and headquartered in Dallas, Texas, ATI is a cyclical industrial materials company whose results are tied closely to commercial aerospace production rates and defense spending.
What does U.S. Physical Therapy (USPH) do?
U.S. Physical Therapy, Inc. runs outpatient physical and occupational therapy clinics across the United States, about 799 locations at September 30, 2026, and an industrial injury prevention (IIP) business that sends athletic trainers and ergonomic specialists into employer worksites. Physical therapy produced about $190 million of Q3 2026 revenue and IIP about $33 million. The company's model is unusual: it buys a majority stake in a local practice, often 50% to 70%, and the founding therapists keep the rest and keep running it. That keeps clinicians invested, but it also means a large slice of profit belongs to partners, and the value of their stakes runs through earnings per share.
ATI vs USPH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ATI drivers: Commercial aerospace recovery and ramp; Mix shift to high-value materials.
- USPH drivers: Hospital affiliations; Visit volume and rate per visit.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: ATI is cyclical and concentrated in aerospace, so any slowdown in commercial aircraft production (for example, Boeing supply-chain or quality problems, or an air-travel downturn) hits demand directly. For USPH, reimbursement is the largest outside risk.
ATI or USPH: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate ATI from USPH. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATI and USPH guides.
ATI vs USPH: the full fundamentals
ATI. ATI's multiple has come down as earnings rose and the shares fell from their high: ~41x trailing GAAP earnings and ~25x forward, against ~55x and ~29x in October. Analysts expect EPS of ~$5.24 for 2026 and ~$6.69 for 2027 on revenue of ~$5.84 billion. Ten analysts carry a strong-buy consensus and a mean target of ~$252, roughly 52% above the November 20 close.
USPH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GAAP earnings are not a useful guide here, because the rising value of partners' stakes is charged against EPS without touching cash, which is why the company and analysts lean on adjusted EPS and EBITDA. Even on those measures the stock is not cheap after rising about 17% in three sessions after the report and holding most of that gain. Published analyst targets moved up after the quarter, with Barrington at $122, and the mean of about $111.50 across six analysts sits roughly 16% above the November 20 close.
Headline figures (approximate, November 2026): ATI shows market cap ~$22.5B (share price ~$165.74 on Nov 20, 2026), revenue (ttm) ~$5.01B, Q3 2026 up ~26.5%, margins (ttm) Gross ~25.1%, operating ~17.6%, net ~11.1%, net income (ttm) ~$556M, EPS ~$4.00; USPH shows revenue (ttm) ~$838 million (Q3 2026 ~$223 million, up ~13% year over year), adjusted ebitda (ttm) ~$100 million (2026 guidance $102 million to $106 million), eps (ttm) Adjusted ~$2.68 (Q3 $0.80); GAAP ~-$1.34 after partner-stake revaluation, valuation ~36x trailing adjusted EPS; ~17x to ~20x trailing adjusted EBITDA; ~29x 2027 consensus EPS of ~$3.37.
The bottom line: ATI vs USPH
ATI and USPH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ATI and USPH exposure against your real portfolio. It is not an investment adviser.
Wondering how ATI or USPH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about ATI Inc.
Ask Walnut's AI anything about ATI and see how it fits what you own.
FAQ
What is the difference between ATI and USPH?
+
ATI Inc. U.S. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ATI or USPH the better stock?
+
Neither is universally better. ATI is the larger incumbent; USPH is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ATI or USPH?
+
On forward P/E (as of November 2026), ATI trades at 24.83x and USPH at 28.55x, so ATI is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ATI and USPH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ATI vs USPH?
+
ATI: ATI is cyclical and concentrated in aerospace, so any slowdown in commercial aircraft production (for example, Boeing supply-chain or quality problems, or an air-travel downturn) hits demand directly. Raw material costs (titanium, nickel) and energy prices are volatile and can squeeze margins. The business is capital-intensive with long lead times, so ramping capacity to meet demand carries execution risk and ties up cash: trailing free cash flow was ~$241 million against ~$730 million of operating cash flow. Competition in specialty alloys is technically demanding but real, and customer concentration among a few large aerospace primes and engine makers adds risk. The stock is volatile and sensitive to aerospace and defense spending cycles and macroeconomic conditions, as the ~23% three-month decline showed. Valuation remains its own risk: at ~41x trailing earnings and ~4.5x sales as of November 2026, the stock leaves little room for a delivery slip, and debt of ~$1.86 billion against ~$442 million of cash means the balance sheet still carries leverage. USPH: Reimbursement is the largest outside risk. Medicare cut therapy rates for several years before 2026, and part of the 2026 increase came from a one-year boost set by Congress, so a cut in the 2027 fee schedule would hit revenue per visit directly. Commercial insurers can also push rates down or tighten visit limits. Labor is the second: physical therapists are in short supply, wages keep rising, and the company's self-insured health plan has been running well above last year's costs. The partnership structure adds complexity. Partners hold about $357 million of redeemable stakes that USPH may have to buy back under put rights, and their rising value has pushed GAAP EPS negative in three of the last four quarters (a $1.04 loss in Q3) even as adjusted earnings grew. The hospital affiliations are concentrated, with 60 of the 72 clinics tied to one New York system, and the company lists termination of an affiliation as a risk. Weather and seasonality move results, as the 31,000 lost visits in Q1 showed. The CFO seat turned over this year, with Nchacha Etta (formerly of Omnicell) starting September 1. Finally, after the jump to about $99.50 and a close near $96 on November 20, 2026, the stock trades within about 15% of the mean analyst target of roughly $111.50, so the cushion between price and published expectations is thin.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ATI or USPH; figures are approximate and dated (as of November 2026). Verify current data before investing.